ArticleHaematologica2019
Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- The Role of the Renin-Angiotensin-Aldosterone System in Hypertensive Emergencies.Biomedicines · 2026Review
- C3 p.Asp1115Asn Variant-associated Atypical Hemolytic Uremic Syndrome with Spontaneous Remission Triggered by Influenza and COVID-19.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- Hypertensive crisis in the critically ill.Annals of intensive care · 2026Review
- Complement activation in secondary thrombotic microangiopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective.Nephrology (Carlton, Vic.) · 2025Review
- Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Review
- What came first, atypical hemolytic uremic syndrome or malignant hypertension: a clinical dilemma.Renal failure · 2024Article
- Medical consult: aHUS, TTP? How to distinguish and what to do.Hematology. American Society of Hematology. Education Program · 2023Article
- Genetic, clinical, and pathological study of patients with severe hypertension-associated renal microangiopathy.Journal of nephrology · 2023Article
- Targeting complement in IgA nephropathy.Clinical kidney journal · 2023Review
- Atypical HUS with multiple complement system mutations triggered by synthetic psychoactive drug abuse: a case report.Journal of nephrology · 2023Article
- Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry.Kidney international reports · 2023Article
- Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry.Journal of nephrology · 2023Article
- Application of C5 inhibitors in glomerular diseases in 2021.Kidney research and clinical practice · 2022Article
- Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure.Research and practice in thrombosis and haemostasis · 2022Article
- Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.Journal of clinical medicine · 2022Review
- Article
- Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia.PLOS global public health · 2022Article
- Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.Nature reviews. Nephrology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A typical hemolytic uremic syndrome (aHUS) is a prototypic thrombotic microangiopathy attributable to complement dysregulation. Hypertensive emergency, characterized by elevation of systolic (>180 mmHg) or diastolic (>120 mmHg) blood pressure together with end-organ damage, can cause thrombotic microangiopathy which may mimic aHUS. We retrospectively evaluated the clinical, biological and complement genetic characteristics of 76 and 61 aHUS patients with and without hypertensive emergency, respectively. Patients with hypertensive emergency-aHUS were more frequently males, with neurological involvement, and a slightly higher hemoglobin level. At least one rare complement variant was identified in 51.3% (39/76) and 67% (41/61) patients with or without hypertensive emergency, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.